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The activity of some small GTPases is regulated by covalent transamidation of serotonin (5-hydro-
pxytryptamien) to glutamine residues of the enzymes. This process is mediated by transglutaminase
(TGase) and is termed ‘‘serotonylation’’. In addition, serotonylation of neural proteins and proteins
of the extracellular matrix such as ﬁbronectin has been demonstrated. Here we show that the cat-
echolamines dopamine (DA) and noradrenaline (NA) inhibit serotonylation of ﬁbronectin and that
DA and NA themselves can be selectively transamidated into ﬁbronectin by TGase. All three biogenic
monoamines also block TGase-mediated transamidation of another monoamine, monodansylacada-
verine, into ﬁbronectin, suggesting a general mechanism of TGase-mediated ‘‘monoaminylation’’.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Outside the central nervous system (CNS) the neurotransmitter
serotonin (5-hydroxytryptamine, 5-HT) plays important roles in
the regulation of small GTPases and blood coagulation. In the latter
process a subpopulation of platelets, so-called ‘‘coated-platelets’’,
retain high levels of procoagulant proteins such as ﬁbrinogen, von
Willebrand factor, factor V and thrombospondin on the cell surface
[1,2]. This process requires transglutaminase (TGase)-mediated
transamidation of 5-HT into glutamine residues of speciﬁc acceptor
proteins, a process which was termed ‘‘serotonylation’’. Tight inter-
action of serotonylated proteins with speciﬁc 5-HT binding sites on
ﬁbrinogen and thrombospondin then contribute to thrombus for-
mation [3,4]. In addition, it has been shown, that serotonylation
of small GTPases is involved in 5-HT release from blood platelets
and insulin secretion from pancreatic beta-cells [5,6]. Very recently,
serotonylation of vascular and neural proteins, as well as of C6
glioma cells and ﬁbronectin has been described [7,8].on behalf of the Federation of Euro
opamine; MDC, monodansyl-
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P. Schloss).In the CNS besides 5-HT also the catecholamines dopamine (DA)
and noradrenaline (NA) are important neurotransmitters which are
implicated in the control of numerous behavioural and physiolog-
ical functions. Having shown that TGase covalently transamidates
[3H]5-HT as well as the ﬂuorescent amine monodansylcadaverine
(MDC) into plasma ﬁbronectin [7], in the current study we sought
to determine whether DA and NA can block TGase-mediated sero-
tonylation and whether TGase may covalently incorporate DA and
NA into ﬁbronectin. Therefore, we have compared the TGase-med-
iated transamidation of [3H]5-HT, [3H]DA and [3H]NA into ﬁbro-
nectin to the one into bovine serum albumin. Moreover, we have
analysed the inhibitory potencies of 5-HT, DA and NA on the
TGase-mediated transamidation of MDC to ﬁbronectin. In addition,
we demonstrated the speciﬁcity of monoaminylation of ﬁbronectin
by identifying the MDC-labelled glutamine residues in ﬁbronectin
by mass spectrometry.
2. Materials and methods
2.1. Expression and puriﬁcation of active recombinant TGase
For expression of the recombinant guinea pig TGase we applied
a method using the chemical chaperone betaine as described [9].
TGase fraction was analysed on SDS–PAGE and Western blottingpean Biochemical Societies.
3422 R. Hummerich et al. / FEBS Letters 586 (2012) 3421–3428using the antibody against TGase2 (Santa Cruz). Enzyme activity
was determined as described [9,10].
2.2. Binding and transamidation of [3H]5-HT into ﬁbronectin
For the determination of binding and transamidation of tritiated
monoamines, we used a modiﬁed ligand binding assay as described
previously [7]. Ten micrograms of plasma ﬁbronectin (Chemicon)
was incubated in a ﬁnal volume of 200 lL buffer (500 mM Tris-ace-
tat, 8.75 mM CaCl2 and 1.25 mM EDTA pH 7.5) with [3H]5-HT, or
[3H]DA or [3H]NA in the presence or absence of recombinant TGase
and/or TGase inhibitors. After 3 h at room temperature the samples
were rapidly ﬁltered through Whatman GF/B glass ﬁbre ﬁlters. The
protein-bound radioactivity retained on the ﬁlters was determined
using a Beckman LS60001IC scintillation counter. Speciﬁc transami-
dation of [3H]monoamines by recombinant TGase was deﬁned as
the difference between total binding and transamidation to ﬁbro-
nectin in the presence of TGAse and simple binding of [3H]mono-
amines to ﬁbronectin in the absence of TGase.
To determine the inhibitory efﬁciencies of unlabelled 5-HT, DA
and NA to block the speciﬁc transamidation of the radiolabelled
monoamines, 10 lg of ﬁbronectin was incubated with 250 nM
[3H]monoamine in presence and absence of recombinant TGase
and with increasing concentrations of unlabelled 5-HT, DA and
NA, respectively. Inhibition of speciﬁc transamidation of [3H]mono-
amine to ﬁbronectin was calculated as the difference between total
binding/transamidation (in the presence of recombinant TGase)
and binding without transamidation (in the absence of TGase) at
the respective concentrations of unlabelled monoamines.
Data were analysed by non-linear regression analysis program
(PRISM GraphPad), which ﬁtted sigmoidal curves to the following
equations:
V ¼ Vmax=ð1þ ½KM=Sn;
and
V=Vmax ¼ ICn50=ðIn þ ICn50Þ
for competition experiments. V represents transamidation rate;
Vmax, maximal transamidation rate; S, substrate concentration; I,
inhibitor concentration; IC50, inhibitor concentration for half maxi-
mal transamidation inhibition; KM, the Michaelis–Menten constant.
2.3. Electrophoresis and ﬂuorography
Gel electrophoresis (SDS–PAGE) in 9% polyacrylamide gels was
performed according to Laemmli [11]. For visualisation of TGase-
mediated conjugation of MDC incorporation, 30 lg of ﬁbronectin
was incubated with 5 mM MDC as described above and subjected
to SDS–PAGE. MDC labelled protein bands were visualised by ﬂuo-
rescence under UV-light.
2.4. Mass spectrometry
The major ﬂuorescent band of MDC-labelled ﬁbronectin (about
230 kDa) was excised from the gel and protein samples were in-gel
digested with trypsin as described previously [12]. Extracted pep-
tides were re-dissolved in 0.5 % triﬂuoroacetic acid and loaded on a
C18 precolumn (Acclaim; Dionex, Idstein, Germany) using a RSLC-
nano HPLC system (Dionex, Idstein, Germany). Peptides were then
eluted with an aqueous-organic gradient, resolved on a C18 col-
umn (Acclaim; Dionex, Idstein, Germany) with a ﬂow rate of
300 nl/min and electrosprayed into a LTQ Orbitrap XL mass spec-
trometer (Thermo Scientiﬁc, Bremen, Germany). A Triversa Auto-
mate (Advion biosciences, Ithaca, NY, USA) was used as ion
source. Each scan cycle consisted of one FTMS full scan and up toseven ITMS dependent MS/MS scans of the seven most intense
ions. Dynamic exclusion (30 s, mass width 20 ppm) and monoiso-
topic precursor selection were enabled. All analyses were per-
formed in positive ion mode.
Extracted MS/MS spectra were searched against the Uniprot/
Swissprot database (Mammalia) using the Phenyx search engine
(GeneBio, Geneva, Switzerland) accepting common variable modi-
ﬁcations and one missed tryptic cleavage. Peptide tolerance was
±10 ppm and MS/MS tolerance was ±0.6 Da. The MDC modiﬁcation
was manually deﬁned and integrated in the databank searches.
2.5. Visualisation of transamidation of C6 cells by protein staining
Cells were plated into 10 cm dishes and grown up for 6 h in
DMEM/F12 medium in the presence or absence of TGase
(200 mU), DA (10 lM) or NA (10 lM). After overnight incubation,
the cells were washed twice with PBS and incubated for 15 min
at 37 C with 4% paraformaldehyde (PFA). After 3 washes with
PBS cells were incubated for 5 min at room temperature with Pon-
ceau S solution (Fluka, 0.1% in 5% acetic acid) and washed three
times with H2O. Cell images were acquired on a Zeiss axiscope
2plus microscope (ﬁlter set 09; – BP 450–490, for ﬂuorescence
imagine) using an 20 planchromat lens. For quantiﬁcation of pro-
tein expression, 20 identical quadrants each containing 10 cells
were randomly picked and ﬂuorescence was measured as the
sum of intensity of all signals acquired with analySIS^B Software.
Image recording and quantiﬁcation of ﬂuorescence were per-
formed by independent operators. The mean intensity measured
in the absence of TGase, DA and NA was taken as 100%. The calcu-
lation of the statistic standard deviations and t-tests were done
with PRISM GraphPad.
3. Results
3.1. TGase-mediated transamidation of [3H]5-HT to ﬁbronectin and
bovine serum albumin
First, we quantitatively characterised transamidation of [3H]5-
HT to ﬁbronectin and bovine serum albumin(BSA) by recombinant
TGase. To this end we puriﬁed recombinant guinea pig TGase as
described in Section 2. In order to discriminate between pure bind-
ing of [3H]5-HT to ﬁbronectin and BSA and covalent transamida-
tion by recombinant TGase we incubated 10 lg ﬁbronectin
(Fig. 1, bar A) or 100 lg BSA (Fig. 1, bar G) with 100 mU TGase
and 250 nM [3H]5-HT; here, radioactivity retained on the glass ﬁ-
bre ﬁlters reﬂects total binding and transamidation of [3H]5HT
by recombinant TGases. In order to determine 5-HT-displaceable
binding/transamidation, we performed the same experiment in
the presence of 500 lM 5-HT (Fig. 1, bars B and H). Incubation with
[3H]5-HT in the absence of recombinant TGase revealed total bind-
ing to ﬁbronectin and BSA, respectively (Fig. 1, bars C and I), and
the same experiment in the presence of 500 lM 5-HT revealed
5-HT-dispaceable binding to ﬁbronectin (Fig. 1, bar D). Finally,
incubation of ﬁbronectin and BSA with [3H]5-HT, recombinant
TGase and 100 lM cystamine, which inhibits recombinant TGase,
revealed total binding of [3H]5HT to both proteins devoid of any
[3H]5-HT transamidation (Fig. 1, bars E and K). Calculating the
difference between A, G (total binding and transamidation by
recombinant TGase to ﬁbronectin and BSA, respectively) and C, I
(pure binding in the absence of TGase) reﬂects speciﬁc [3H]5-HT
transamidation by recombinant TGase. In three independent
experiments 125.3 ± 4.8 pmol [3H]5-HT were transamidated to
1 mg ﬁbronectin. No TGase-mediated incorporation of [3H]5-HT
was observed into BSA indicating the speciﬁcity of ﬁbronectin
serotonylation. Saturation experiments revealed a maximal
Fig. 1. Binding and transamidation of [3H]5-HT to ﬁbronectin and bovine serum albumin (BSA). 10 lg ﬁbronectin (bars A–F) and 100 lg BSA (bars G–K) were incubated with
250 nM [3H]5-HT and 100 mU TGase (bar A and G) for 3 h at room temperature as indicated. In bar B/H and D 500 lM unlabelled 5-HT was added to determine unspeciﬁc
binding/transamidation. In bar E and K ﬁbronectin and BSA were incubated with 500 lM cystamine to determine speciﬁc and unspeciﬁc binding by inhibition of TGase. Bar F
presents, in presence of 500 lM 5-HT and cystamine, inhibition of speciﬁc and unspeciﬁc binding. Speciﬁc transamidation of [3H]5-HT mediated by recombinant TGase2
calculated as the difference of A (=total binding and transamidation by recombinant TGase) and C (=total binding), was 123.1 pmol/mg in this representative experiment. The
inset shows saturation of [3H]5-HT binding (, corresponding to bar C), the sum of [3H]5-HT binding and transamidation (j, corresponding to bar A) and speciﬁc
transamidation as calculated from the difference between A and C-values (.). The maximal incorporation for [3H]5-HT into ﬁbronectin in this representative experiment was
433.3 pmol/mg with a KM = 677.3 nM. Error bars (shown when larger as the symbol used) represent standard error of the mean.
Fig. 2. Inhibition of [3H5-HT transamidation to ﬁbronectin. The IC50 values for the inhibition of [3H]5-HT transamidation to ﬁbronectin, obtained in these particular
experiments were 549 nM for unlabelled 5-HT, 224 nM for DA and 256 nM for NA.
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with a KM value of 794.1 ± 68.5 nM (n = 3).
3.2. Inhibition of [3H]5-HT transamidation to ﬁbronectin by 5-HT, DA
and NA
Next we analysed whether transamidation of [3H]5-HT to ﬁbro-
nectin is inhibited by unlabelled 5-HT, DA and NA as described in
Section 2. As shown in Fig. 2, all three monoamine dose-depen-
dently fully inhibited speciﬁc TGase-mediated incorporation of
[3H]5-HT into ﬁbronectin. Non-linear regression analysis revealedIC50 values for 5-HT = 561 ± 19.3 nM (n = 3), DA = 235 ± 21.7 nM
(n = 3) and NA = 259 ± 21.0 nM (n = 3). Representative experiments
are shown in Fig. 2.
3.3. TGase-mediated transamidation of [3H]DA to ﬁbronectin and
bovine serum albumin
Because DA dose-dependently inhibited speciﬁc transamidation
of [3H]5-HT into ﬁbronectin, we next characterised TGase-medi-
ated incorporation of [3H]DA into ﬁbronectin and BSA. As shown
in Fig. 3, we performed the same set of experiments as described
Fig. 3. Binding and transamidation of [3H]DA to ﬁbronectin. 10 lg ﬁbronectin (bars A–F) and 100 lg bovine serum albumin (bars G–K) were incubated with 200 nM [3H]DA
and 100 mU TGase (bar A and G) for 3 h at room temperature as indicated. In bar B/H and D 500 lM unlabelled DA was added to determine unspeciﬁc binding/
transamidation. In bar E and K ﬁbronectin and bovine serum albumin were incubated with 500 lM cystamine to determine speciﬁc and unspeciﬁc binding by inhibition of
exogenous TGase. Bar F presents, in presence of 500 lM DA and cystamine, inhibition of speciﬁc and unspeciﬁc binding. In this particular experiments transamidation of
[3H]DA mediated by recombinant TGase2 was calculated as the difference of A (total binding and transamidation by recombinant TGase) and C (=total binding) and reﬂected
102.3 pmol/mg. The inset shows saturation of [3H]DA binding (, corresponding to bar C), the sum of [3H]DA binding and transamidation (j, corresponding to bar A) and
speciﬁc transamidation as calculated from the difference between A and C-values (.). The maximal incorporation for [3H]DA in the representative experiment was
391.5 pmol/mg with a KM = 434.4 nM. Error bars are shown where larger than the symbol used and represent standard error of the mean.
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culated the speciﬁc transamidation of [3H]DA as the difference be-
tween A, G (binding and transamidation by recombinant TGase)
and C, I (binding in the absence of TGase). In three independent
experiments 103.8 ± 10.2 pmol [3H]DA were transamidated to
1 mg ﬁbronectin; no TGase-mediated incorporation of [3H]DA
was observed into BSA. Saturation experiments revealed a maxi-
mal incorporation of [3H]DA into ﬁbronectin of 431 ± 34.1 pmol/
mg ﬁbronectin with a KM value of 448.2 ± 14.2 nM (n = 4).
3.4. Inhibition of [3H]DA transamidation to ﬁbronectin by 5-HT, DA
and NA
Next we determined the potency of unlabelled 5-HT, DA and NA
to inhibit the TGase-mediated incorporation of [3H]DA to ﬁbronec-
tin. As shown in Fig. 4, only 5-HT and NA completely inhibited spe-
ciﬁc TGase-mediated incorporation of [3H]DA into ﬁbronectin in a
dose-dependent manner whereas DA maximally inhibited
89.7 ± 1.1% of [3H]DA incorporation (n = 3). Non-linear regression
analysis revealed IC50 values for 5-HT = 2.2 ± 0.04 mM (n = 3),
DA = 989.4 ± 20.1 nM (n = 3) and NA = 50.6 ± 0.7 lM (n = 3). Repre-
sentative experiments are shown in Fig. 4.3.5. TGase-mediated transamidation of [3H]NA to ﬁbronectin and
bovine serum albumin
Next we next characterised TGase-mediated incorporation of
[3H]NA into ﬁbronectin and BSA. As shown in Fig. 5, we performed
the same set of experiments as described above for the transami-
dation of [3H]5-HT and [3H]DA to both proteins and calculated
the speciﬁc transamidation of [3H]NA as the difference between
A, G (total binding and transamidation by recombinant TGase)
and C, I (total binding in the absence of TGase). In three indepen-
dent experiments 45.8 ± 3.3 pmol [3H]NA were transamidated to
1 mg ﬁbronectin, whereas no TGase-mediated incorporation of
[3H]NA was observed into BSA.
Saturation experiments revealed a maximal incorporation of
[3H]NA into ﬁbronectin of 154 ± 20.4 pmol/mg ﬁbronectin with a
KM value of 441.5 ± 12.3 nM (n = 4).
3.6. Inhibition of [3H]NA transamidation to ﬁbronectin by 5-HT, DA
and NA
As shown in Fig. 6, 5-HT and NA dose-dependently inhibited
speciﬁc TGase-mediated incorporation of [3H]NA into ﬁbronectin
Fig. 4. Inhibition of [3H]DA transamidation to ﬁbronectin. The IC50 values for the inhibition of [3H]DA transamidation to ﬁbronectin, obtained in this particular experiment
was 953 nM for unlabelled DA, 2.3 mM for 5-HT, and 51.5 lM for NA.
Fig. 5. Binding and transamidation of [3H]NA to ﬁbronectin. 10 lg ﬁbronectin (bar A-F) and 100 lg bovine serum albumin (G-K) were incubated with 200 nM [3H]NA and
100 mU TGase (bar A and G) for 3 h at room temperature as indicated. In bars B/H and D 500 lM unlabelled NA was added to determine unspeciﬁc binding/transamidation. In
bars E and K ﬁbronectin and bovine serum albumin were incubated with 500 lM cystamine to inhibit exogenous TGase activity. Bar F presents, in presence of 500 lMNA and
cystamine, inhibition of speciﬁc and unspeciﬁc binding. In this particular experiments transamidation of [3H]NA mediated by recombinant TGase2 was calculated as the
difference of A (total binding and transamidation by recombinant TGase) and C (total binding without transamidation) and reﬂected 44.6 pmol/mg. The inset shows
saturation of [3H]DA binding (, corresponding to bar C), the sum of [3H]DA binding and transamidation (j, corresponding to bar A) and speciﬁc transamidation as calculated
from the difference between A and C-values (.). The maximal incorporation for [3H]NA in the representative experiments was 189.9 pmol/mg with a KM = 426.3 nM. Error
bars are shown where larger than the symbols used and represent standard error of the mean.
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1.1 ± 0.03 lM (n = 3). DA, however, only b maximally 77.2 ± 1.8%
of TGase-mediated [3H]NA incorporation with an IC 50 value of
2.1 ± 0.05 lM (n = 3).
3.7. Inhibition of TGase-mediated incorporation of MDC into
ﬁbronectin by 5-HT, DA and NA
Recently we had shown that TGase covalently transamidates
the ﬂuorescent monoamine MDC into ﬁbronectin. After subjection
to SDS–PAGE MDC-labelled ﬁbronectin could be visualised by UV
illumination. MDC-labelling was inhibited by cystamine and
dose-dependently reduced in the presence of 5-HT [7]. Here, wecompared the potencies of 5-HT, DA and NA to inhibit TGase-med-
iated transamidation of MDC to ﬁbronectin. As shown in Fig. 7,
MDC-labelling was partly diminished in the presence of 40 mM
5-HT, more strongly diminished in the presence of 40 mM NA,
and totally blocked by 10 mM DA.
3.8. Identiﬁcation of MDC-labelled glutamine residues in ﬁbronectin
In order to identify MDC-labelled glutamine (Gln; Q) residues of
ﬁbronectin after SDS–PAGE we excised ﬂuorescent bands of about
230 kDa, trypsinized the protein in-gel and performed mass spec-
trometry (MS) as described in Section 2. As shown in Table 1, ele-
ven MDC-labelled Gln residues were identiﬁed.
Fig. 6. Inhibition of [3HNA transamidation to ﬁbronectin. The IC50 values for the inhibition of [3H]NA transamidation to ﬁbronectin, obtained in this particular experiments
were 1.0 lM for unlabelled NA, 124 lM for 5-HT, and 2.3 lM for DA.
Fig. 7. TGase mediated incorporation of MDC into human plasma ﬁbronectin. 30 lg ﬁbronectin were incubated with 5 mM MDC in the presence of 200 mU recombinant
TGase, cystamine, 5-HT, DA and NA as indicated and as described in Section 2. (a) Coomassie stain of assay panel (b), ﬂuorescence of MDC incorporation.
Table 1
Modiﬁed amino acid residues are bold and underscored; z charge; m/zmass-over-charge; AA amino acid. The AA-position refers to ﬁbronectin (P02751). Peptides were identiﬁed
with Phenyx (BeneBio). Modiﬁed Glutamine residues in ﬁbronectin.
# Amino acid sequence z m/z AA-Position Modiﬁcation
1 K/HYQINQQWER/T 3 573.94 27–36 1 MDC
2 R/HTSVQTTSSGSGPFTDVR/A 3 728.013 273–290 1 MDC
R/HTSVQTTSSGSGPFTDVR/A 2 1091.515 273–290 1 MDC
3 K/GLKPGVVYEGQLISIQQYGHQEVTR/F 3 1039.88 670–694 1 MDC
4 R/WSRPQAPITGYR/I 3 583.968 831–842 1 MDC
5 K/LGVRPSQGGEAPR/E 3 547.956 1117–1129 1 MDC
6 R/TEIDKPSQMQVTDVQDNSISVK/W 3 927.454 1540–1561 1 MDC
R/TEIDKPSQMQVTDVQDNSISVK/W 3 932.786 1540–1561 1 MDC, 1 Oxidation_M
R/TEIDKPSQMQVTDVQDNSISVK/W 3 1033.501 1540–1561 2 MDC
R/TEIDKPSQMQVTDVQDNSISVK/W 3 1139.547 1540–1561 3 MDC
7 R/RPGGEPSPEGTTGQSYNQYSQR/Y 3 905.413 2125–2146 1 MDC
R/RPGGEPSPEGTTGQSYNQYSQR/Y 3 1011.463 2125–2146 2 MDC
R/RPGGEPSPEGTTGQSYNQYSQR/Y 3 1117.509 2125–2146 3 MDC
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Recently we had shown that TGase-mediated transamidation of
serotonin to living C6 glioma cells induced an aggregation of extra-
cellular protein matrices adjacent to and between single cells [7].
Consequently, we now studied whether ‘‘dopaminylation’’ andnoradrenylation’’ of C6 glioma cells also affects extracellular pro-
tein expression. To this intent we incubated C6 cells with 10 lM
DA or 10 lMNA in the absence or presence of TGase and visualised
protein expression by staining with Ponceau S as described in Sec-
tion 2. Bright-ﬁeld microscopy revealed that individual cell mor-
phology was not affected by TGase treatment. Protein staining
R. Hummerich et al. / FEBS Letters 586 (2012) 3421–3428 3427with Ponceau S, revealed more intense protein expression on and
between TGase-treated C6 cells in the presence of DA or NA as
compared to untreated cells (Fig. 8A and B). In order to compare
protein expression between TGase-treated versus untreated cells
more accurately, Ponceau S staining was excited at 450 nM
(Fig. 8C) and the resulting ﬂuorescence was quantiﬁed as described
in Section 2. As shown in Fig. 8D, total protein expression on and
between C6 cells quantiﬁed by Ponceau staining was augmented
to 180.5 ± 5.8% by the addition of 10 lM DA and 180.7 ± 5.5% byFig. 8. TGase-mediated transamidation of DA and NA into living C6 glioma cells. Cells wer
the top of the ﬁgure. Protein staining with Ponceau S; arrow heads indicate more pronou
C6 cells as compared to not-monoaminylated cells. B, represents a zoom from A. C, ﬂuore
Ponceau ﬂuorescence revealed enhanced protein staining to 180.5 ± 5.8% by the addition o
TGase as compared to non-treated cells (100 ± 3.2%). The data are the mean out of fourthe addition of 10 lM Na in the presence of 200 mU TGase (mean
out of four independent experiments incl. S.E.M. values).
4. Discussion
The biogenic monoamine 5-HT had been shown to be transam-
idated inside cells to small GTPases rendering these proteins active
[5,6]. This process is mediated by TGases and has been termed
‘‘serotonylation’’. Recently also the speciﬁc serotonylation of ﬁbro-e incubated in the absence of 200 mU TGase, 10 lMDA or 10 lMNA as indicated on
nced extracellular protein accumulation between and adjacent to monoaminylated
scence of Ponceau staining upon excitation at 450 nm; D, quantitative evaluation of
f 10 lMDA and 180.7 ± 5.5% by the addition of 10 lMNA in the presence of 200 mU
independent experiments incl. S.E.M. values. Bars represent 100 lm.
3428 R. Hummerich et al. / FEBS Letters 586 (2012) 3421–3428nectin, a protein of the extracellular matrix, has been reported
[7,8]. In the latter study it had been shown, that TGase also can
selectively transamidate the ﬂuorescent monoamine MDC to ﬁbro-
nectin and that this transamidation was reduced by 5-HT. The ﬁrst
major ﬁnding of our present study is that TGase-mediated transa-
midation of [3H]5-HT and MDC into ﬁbronectin is blocked by DA
and NA. Moreover, similarly to our ﬁndings for [3H]5-HT [7], TGase
also covalently incorporated [3H]DA and [3H]NA into ﬁbronectin,
but not into BSA. Saturation experiments revealed, that the maxi-
mal incorporation rate of all three monoamines did not differ sig-
niﬁcantly (5-HT: 425 ± 60; DA 431 ± 14 and NA: 441 ± 61 pmol/mg
ﬁbronectin), whereas the KM values for transamidation by TGase
varied from 154 nM for [3H]NA over 448 nM for DA to 749 nM
for 5-HT. These ﬁndings suggest that TGase transamidates the
same amount of glutamine residues on ﬁbronectin with 5-HT, DA
and NA but with different afﬁnities. This is also reﬂected by the
results of our inhibition experiments where the three monoamines
blocked the transamidation of radiolabelled monoamines with
substantial different efﬁciencies. At this point it should be noted
that with the exception of the inhibition of transamidation of
[3H]5-HT by unlabelled 5-HT none of the other displacement pro-
ﬁles followed an adequate non-linear regression ﬁt. The unusual
inhibition proﬁles observed in the displacement studies were
reproducible in each single experiment.
Monoamine incorporation into glutamine residues is known to
take place at a thioester-intermediate formation between a cys-
teine residue of the TGase and the glutamine residue of the donor
protein [13,14]. Thus our heterogeneous displacement curves sug-
gested multiple glutamine residues in ﬁbronectin as target for
transamidation which are differentially accessible to 5-HT, DA
and NA. In order to determine possible target glutamine residues
for monoaminylation we isolated the ﬂuorescent MDC-labelled
ﬁbronectin band at 230 kDa after SDS–PAGE and identiﬁed MDC-
modiﬁed glutamine residues by mass spectrometry. Using this ap-
proach we found eleven glutamine residues which were modiﬁed
by MDC. The differential accessibility of these residues to the dif-
ferent monoamines is reﬂected by the ﬁnding that MDC-transami-
dation is most effective blocked by DA > NA > 5-HT (see Fig. 7).
In addition, transamidation of living C6 glioma cells with DA
and NA by recombinant exogenous TGase led to a profound protein
aggregation adjacent to and between single cells without affecting
the cell morphology. Here, the extent of extracellular protein
aggregation upon ‘‘dopaminylation’’ and ‘‘noradrenylation’’ was
comparable to the one which we had measured upon serotonyla-
tion of C6 cells in a recent study [7]. These ﬁndings suggest a com-
mon effect of TGase-mediated ‘‘monoaminylation’’ of extracellular
proteins.
In all our experiments we have used recombinant TGase2,
because this enzyme is the major TGase isoform in the brain where
it is expressed both intra- and extra-cellular [13,14]. TGase2 had
also been shown to serotonylate proteins of smooth muscle cells
[8]. Very recently it has been shown in TGase2-knock-out mice that
TGase2-independent TGase activity exists in the vasculature and
that aortic smooth muscle cells also express TGase 1 and TGase4
in addition to TGase2 [15]. These ﬁndings raise the questionwhether other TGase isoforms may also catalyse a general mecha-
nism of monoaminylation comparable to TGase2.
In summary, our ﬁndings on TGase-mediated transamidation of
the monoamines 5-HT, DA, NA and MDC into ﬁbronectin suggest a
more general mechanism of ‘‘monoaminlyation’’ beyond the
already described mechanism of serotonylation. Comparable to
our ﬁndings here also the transamidation of NA to proteins of vas-
cular smooth muscle cells has been reported [16] and a new role
for biogenic monoamines has also been recently discussed in the-
ory with respect to the regulation of small GTPases, G-proteins,
lipid signalling and metabolic enzymes [17]. Here we present the
ﬁrst compelling biochemical evidence to support this hypothesis
and hope that these ﬁndings will spur further studies on the iden-
tiﬁcation of other speciﬁc target proteins for monoaminylation and
on the physiological role of monoaminylation.
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